Clinical Trial

Evaluating Treatable Traits Across the Spectrum of Chronic Obstructive Airways Disease

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Respiratory disease affects one in five people and is a leading cause of global morbidity and mortality. Chronic obstructive airways diseases encompass conditions characterised by expiratory airflow limitation, exertional dyspnoea, activity limitation and impaired quality of life. The most common conditions include chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, cystic fibrosis and primary ciliary dyskinesia. In recent years, there has been concerted effort in the scientific and respiratory medicine community to improve the diagnosis and management of chronic obstructive airways diseases using personalised or precision medicine (i.e., tailoring therapies and interventions according to specific "treatable traits") and identifying phenotypes or endotypes using validated biomarkers. To date, however, research in this setting has primarily focussed on people with COPD and asthma, with limited studies in other forms of chronic obstructive airways diseases. The aim of this study is therefore two-fold; first, to compare pulmonary physiology (i.e., large and small airway involvement) and extra-pulmonary manifestations across the spectrum of chronic obstructive airways, and second, to determine how disease-specific treatable traits associate with physical activity and health-related quality of life.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-07-27; most recent amendment 2025-03-25.
Status change: Not Yet Recruiting → Recruiting 2023-11-28
Trial Details
NCT Number NCT05976919
Lead Sponsor University of Leeds
Collaborators: The Leeds Teaching Hospitals NHS Trust
Conditions Airway Disease
Enrollment 100 participants
Start Date 2023-10-01
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-30